Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling

• Published in: Cell communication and signaling Vol. 16; no. 1; pp. 51 - 12
• Main Authors: Csoboz, Balint, Gombos, Imre, Tatrai, Eniko, Tovari, Jozsef, Kiss, Anna L, Horvath, Ibolya, Vigh, Laszlo
• Format: Journal Article
• Language: English
• Published: England BioMed Central 29-08-2018; BMC
• Subjects: Breast cancer; Cancer; Cancer therapies; Caveolae; Cell cycle; Chemotherapy; Cyclin D1; Dephosphorylation; Electron microscopy; Genotoxicity; Immunoprecipitation; Integrin; Liver; Localization; Melanoma; Membrane structure; Phosphatase; PRL3; Protein composition; Proteins; Proteomes; Rac1; Rac1 protein; Tumor cells; Tumor therapy; Tumors; Western blotting; United States > US; Integrin; Rac1; Caveolae; PRL3; Tumor therapy
• ISSN: 1478-811X; 1478-811X
• DOI: 10.1186/s12964-018-0264-8

The outcome of cancer therapy is greatly defined by the ability of a tumor cell to evade treatment and re-establish its bulk mass after medical interventions. Consequently, there is an urgent need for the characterization of molecules affecting tumor reoccurrence. The phosphatase of regenerating liver 3 (PRL3) protein was recently emerged among the targets that could affect such a phenomenon.
The expression induction of PRL3 in melanoma cells treated with chemotherapeutic agents was assessed by western blotting. The effect of PRL3 expression on cancer growth was investigated both in vitro and in vivo. The association of PRL3 with the caveolae structures of the plasma membrane was analyzed by detergent free raft purification. The effect of PRL3 expression on the membrane organization was assayed by electron microscopy and by membrane biophysical measurements. Purification of the plasma membrane fraction and co-immunoprecipitation were used to evaluate the altered protein composition of the plasma membrane upon PRL3 expression.
Here, we identified PRL3 as a genotoxic stress-induced oncogene whose expression is significantly increased by the presence of classical antitumor therapeutics. Furthermore, we successfully connected the presence of this oncogene with increased tumor growth, which implies that tumor cells can utilize PRL3 effects as a survival strategy. We further demonstrated the molecular mechanism that is connected with the pro-growth action of PRL3, which is closely associated with its localization to the caveolae-type lipid raft compartment of the plasma membrane. In our study, PRL3 was associated with distinct changes in the plasma membrane structure and in the caveolar proteome, such as the dephosphorylation of integrin β1 at Thr788/Thr789 and the increased partitioning of Rac1 to the plasma membrane. These alterations at the plasma membrane were further associated with the elevation of cyclin D1 in the nucleus.
This study identifies PRL3 as an oncogene upregulated in cancer cells upon exposure to anticancer therapeutics. Furthermore, this work contributes to the existing knowledge on PRL3 function by characterizing its association with the caveolae-like domains of the plasma membrane and their resident proteins.